Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2002

View Archived Issues

First antagonists to demonstrate potency and selectivity for alpha4beta7 compared to other integrins

Intraperitoneal injection of PYY3-36 inhibits food intake, reduces weight gain in rats and mice

WR-279396 accelerates cure time of cutaneous leishmaniasis

New inhibitors of memapsin 2 with potential in Alzheimer's disease

New safety data approved for Malarone

BattellePharma and Pharmacia to develop inhalable treatment

Pirfenidone attenuates neointima development after angioplasty in rats

Maxim commences clinical study of MX-8899 for the treatment of oral mucositis

Neulasta approved in E.U.

Phase IIa trial commences with bimosiamose as treatment for asthma

Synthesis and SAR studies of selective COX-2 inhibitors disclosed by Pacific Corporation

Genz-34940 delays induction of acute EAE in mice

GW-500580X normalizes glucose and insulin levels in obese mice

Fuzeon early access program opens in the U.S.

Trisenox rolling out across Europe for treatment of APL

GlaxoSmithKline submits NDA for once-daily bupropion hydrochloride

New low-dose strength of Vivelle-Dot launched for prevention of menopausal osteoporosis

Approvable letter for Genelabs Technologies' Prestara, formerly Aslera

Aventis declines option to develop pagoclone

Hepsera chosen as U.S. trade name for adefovir dipivoxil

New phase I/II trial to evaluate Onco TCS in acute lymphoblastic leukemia

Selective PPARgamma agonists with utility in the treatment of diabetes

Roche claims alpha1A and alpha1B adrenergic receptor antagonists

Sodium channel modulators claimed for pain and migraine

More telomerase inhibitors disclosed by Geron and Kyowa Hakko

Estrogen receptor ligands jointly claimed by Karo Bio and Merck & Co.